Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051531 | PMC |
| http://dx.doi.org/10.1513/AnnalsATS.201711-842ED | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: The primary aim of this study was to compare resource utilization between lower and higher-risk brief resolved unexplained events (BRUE) in the general (GED) and pediatric (PED) emergency departments.
Methods: We conducted a retrospective chart review of BRUE cases from a large health system over 6-and-a-half years. Our primary outcome was the count of diagnostic tests per encounter.
Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase.
Infect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDFPractical considerations towards the collection of patient reported outcome data among hematopoietic cell transplant recipients.
Patient
September 2025
Patient Services, Anthony Nolan, 2 Heathgate Place, London, NW3 2NU, UK.
Background: There is increasing interest in using patient-reported outcome measures (PROMs) to assess quality of life (QoL) following hematopoietic cell transplant (HCT). However, there is limited consensus on how such data should be collected within HCT services. This survey study investigated health professionals (HCPs) views towards QoL data collection and factors affecting the use of PROMs within HCT centres in the UK.
View Article and Find Full Text PDFPhenotypic age acceleration as a novel predictor of benign prostatic hyperplasia: a prospective cohort study.
Geroscience
September 2025
Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
This study aims to investigate the predictive value of combined phenotypic age and phenotypic age acceleration (PhenoAgeAccel) for benign prostatic hyperplasia (BPH) and develop a machine learning-based risk prediction model to inform precision prevention and clinical management strategies. The study analyzed data from 784 male participants in the US National Health and Nutrition Examination Survey (NHANES, 2001-2008). Phenotypic age was derived from chronological age and nine serum biomarkers.
View Article and Find Full Text PDFDrugs Withdrawn from the Canadian Market for Safety and Effectiveness Reasons, 1990-2024: A Cross-Sectional Study.
Drug Saf
September 2025
School of Health Policy and Management, York University, 4700 Keele St., Toronto, ON, M3J 1P3, Canada.
Introduction: At times it is necessary to withdraw drugs after they have been approved because of lack of effectiveness or safety concerns. Health Canada does not keep a list of withdrawn drugs.
Objective: The aim of this study was to generate a list of all drugs approved since 1990 and subsequently withdrawn from the Canadian market for safety or effectiveness reasons until the end of 2024.